Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “KRAS Gene Mutation Negative”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Testing effectiveness (Phase 2)Study completedNCT01326000
What this trial is testing

RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hoffmann-La Roche 169
Testing effectiveness (Phase 2)Study completedNCT00779454
What this trial is testing

Combined Biological Treatment and Chemotherapy for Patients With Inoperable Cholangiocarcinoma

Who this might be right for
Cholangiocarcinoma
Vejle Hospital 72
Testing effectiveness (Phase 2)Study completedNCT01229150
What this trial is testing

Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...

Who this might be right for
Non Small Cell Lung Carcinoma
National Cancer Institute (NCI) 89
Early research (Phase 1)Active Not RecruitingNCT07474168
What this trial is testing

T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Who this might be right for
Tumor
Zhejiang University 9
Testing effectiveness (Phase 2)Study completedNCT02278133
What this trial is testing

Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations

Who this might be right for
Metastatic Colorectal Cancer
Array BioPharma 20
Not applicableStudy completedNCT01834014
What this trial is testing

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Who this might be right for
Liver MetastasisColorectal Cancer
EPS Corporation 110
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Large-scale testing (Phase 3)Study completedNCT01550055
What this trial is testing

Study of CMAB009 to Treat KRAS Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Shanghai Zhangjiang Biotechnology Limited Company 512
Testing effectiveness (Phase 2)Ended earlyNCT01060423
What this trial is testing

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hans-Joachim Schmoll, MD 8
Testing effectiveness (Phase 2)Study completedNCT01443377
What this trial is testing

Neoadjuvant Radiochemotherapy Combined With Panitumumab in Locally Advanced KRAS Wild-type Rectal Cancer

Who this might be right for
Rectal Cancer
National Center for Tumor Diseases, Heidelberg 48
Not applicableEnded earlyNCT01074333
What this trial is testing

An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment

Who this might be right for
Colorectal Neoplasm
Merck KGaA, Darmstadt, Germany 146
Testing effectiveness (Phase 2)Active Not RecruitingNCT06682572
What this trial is testing

Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients

Who this might be right for
Low Grade Serous Ovarian CancerOvarian Cancer
Verastem, Inc. 16
Testing effectiveness (Phase 2)UnknownNCT01384994
What this trial is testing

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Who this might be right for
Colorectal CancerKRAS WildtypeAfter Resection of Liver Metastases
PD Dr. med. Volker Heinemann 111
Testing effectiveness (Phase 2)Active Not RecruitingNCT04117945
What this trial is testing

Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

Who this might be right for
BRAF V600E NegativeKRAS Gene Mutation NegativeLocally Advanced Unresectable Colorectal Adenocarcinoma+10 more
Academic and Community Cancer Research United 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04625270
What this trial is testing

Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation

Who this might be right for
Low Grade Ovarian Serous AdenocarcinomaOvarian Cancer
Verastem, Inc. 225
Testing effectiveness (Phase 2)Study completedNCT00553254
What this trial is testing

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

Who this might be right for
Carcinoma, Non Small Cell Lung
Pfizer 55
Testing effectiveness (Phase 2)Study completedNCT01226719
What this trial is testing

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Who this might be right for
Colorectal Cancer
SCRI Development Innovations, LLC 15
Testing effectiveness (Phase 2)Ended earlyNCT01351038
What this trial is testing

Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma

Who this might be right for
KRAS Wild TypeResectable Type II Gastric Adenocarcinoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 43
Large-scale testing (Phase 3)Ended earlyNCT01309126
What this trial is testing

Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Who this might be right for
Colorectal Cancer
HiberCell, Inc. 217
Early research (Phase 1)Study completedNCT06056024
What this trial is testing

Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus

Who this might be right for
Solid Tumor, KRAS Mutation
Boehringer Ingelheim 47
Next Page